A Phase 1 Study with an Expansion Cohort of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

Protocol No
ECOG-E4412
Principal Investigator
Timothy Fenske
Phase
I
Summary
The purpose of this study is to test the safety of the combination of two drugs: brentuximab vedotin which is approved for use in relapsed Hodgkin lymphoma, and ipilimumab a drug which stimulates your immune system, which is approved for use in other cancers, but is investigational for Hodgkin lymphoma. We want to find out what effects, good and/or bad, these drugs used together at different dose levels have on you and your relapsed or refractory Hodgkin lymphoma. This drug combination is investigational. Brentuximab vedotin has been FDA approved used by itself to treat Hodgkin lymphoma that has relapsed after 2 chemotherapy treatments, or failed to respond to chemotherapy. Ipilimumab is investigational, meaning it has not been approved by the FDA for use in your cancer, although it has been FDA approved for use in other cancers.
Description
We want to find out what effects, good and/or bad, the drug combination of brentuximab vedotin and ipilimumab used together at different dose levels have on you and your relapsed or refractory Hodgkin lymphoma.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: